Literature DB >> 20738809

Detection of early amnestic mild cognitive impairment without significantly objective memory impairment: a case-controlled study.

Norio Murayama1, Eizo Iseki, Hiroshige Fujishiro, Ryoko Yamamoto, Kazumi Ota, Masaru Suzuki, Kiichi Nagashima, Heii Arai, Kiyoshi Sato.   

Abstract

BACKGROUND: We encountered eight early amnestic mild cognitive impairment (aMCI) patients (early MCI group) who did not fulfill the diagnostic criteria for aMCI. We compared the scores of neuropsychological examinations as well as the cerebral metabolic rate for glucose consumption (CMRglc) decrease on (18)F-FDG PET examination between the early MCI group and 10 aMCI patients (MCI group) or six normal elderly subjects (normal group), to examine whether the current diagnostic criteria can detect early-stage aMCI.
METHODS: The three groups underwent Mini-Mental State Examination (MMSE), Wechsler Adult Intelligence Scale - Third Edition (WAIS-III), Wechsler Memory Scale Revised (WMS-R), magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) examinations.
RESULTS: The early MCI group did not show significant memory impairment of 1.0 SD or other cognitive dysfunctions on neuropsychological examinations, and did not fulfill the diagnostic criteria of aMCI. With one-way anova and Tukey's HSD post-hoc test, the early MCI group showed the highest scores for WAIS-III, whereas the MCI group showed the lowest scores for WMS-R, although there were no significant differences between the early MCI and normal groups. In order to show a discrepancy in scores between WAIS-III and WMS-R, we subtracted the scores of WMS-R from WAIS-III. Consequently, the normal group showed significantly smaller differences in scores than the other groups, although there were no significant differences between the early MCI and MCI groups. (18)F-FDG PET recognized a CMRglc decrease in the posterior cingulate gyrus and/or part of the parietotemporal area in both the MCI and early MCI groups, of which the extent and magnitude were weaker in the early MCI group. The normal group did not show a significant CMRglc.
CONCLUSIONS: The early MCI group should be included in aMCI not only based on the discrepancy between intelligence and memory scores, but also based on the (18)F-FDG PET findings. The combination of these examinations would make it possible to diagnose early-stage aMCI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738809     DOI: 10.1111/j.1479-8301.2010.00316.x

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  5 in total

Review 1.  Brain PET in the diagnosis of Alzheimer's disease.

Authors:  Charles Marcus; Esther Mena; Rathan M Subramaniam
Journal:  Clin Nucl Med       Date:  2014-10       Impact factor: 7.794

2.  Changes in thalamic connectivity in the early and late stages of amnestic mild cognitive impairment: a resting-state functional magnetic resonance study from ADNI.

Authors:  Suping Cai; Liyu Huang; Jia Zou; Longlong Jing; Buzhong Zhai; Gongjun Ji; Karen M von Deneen; Junchan Ren; Aifeng Ren
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

3.  Altered Functional Connectivity of Fusiform Gyrus in Subjects with Amnestic Mild Cognitive Impairment: A Resting-State fMRI Study.

Authors:  Suping Cai; Tao Chong; Yun Zhang; Jun Li; Karen M von Deneen; Junchan Ren; Minghao Dong; Liyu Huang
Journal:  Front Hum Neurosci       Date:  2015-08-27       Impact factor: 3.169

4.  Differences in learning rates for item and associative memories between amnestic mild cognitive impairment and healthy controls.

Authors:  Pengyun Wang; Juan Li; Huijie Li; Shouzi Zhang
Journal:  Behav Brain Funct       Date:  2013-07-25       Impact factor: 3.759

5.  Early indications of future cognitive decline: stable versus declining controls.

Authors:  Angela Rizk-Jackson; Philip Insel; Ronald Petersen; Paul Aisen; Clifford Jack; Michael Weiner
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.